Mometasone
- Generic Name
- Mometasone
- Brand Names
- Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30Cl2O6
- CAS Number
- 83919-23-7
- Unique Ingredient Identifier
- 04201GDN4R
- Background
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its ...
- Indication
Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years. Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.
...
- Associated Conditions
- Asthma, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergic Rhinitis, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects
- Associated Therapies
- -
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Jeffrey Glassberg
- Target Recruit Count
- 54
- Registration Number
- NCT02061202
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT01861145
- Locations
- 🇨🇦
Synergy Respiratory Care Centre, Sherwood Park, Alberta, Canada
🇨🇦Stollery Children's Hospital, Edmonton, Alberta, Canada
Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- PH&T S.p.A.
- Target Recruit Count
- 360
- Registration Number
- NCT01702103
- Locations
- 🇦🇷
Swiss Medical Group, Buenos Aires, Capital Federal, Argentina
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 1220
- Registration Number
- NCT01673659
An Open-label Study to Identify Molecular Markers of Steroid Resistance
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT01616160
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT01609478
- Locations
- 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 739
- Registration Number
- NCT01555151
- Locations
- 🇺🇦
Novartis Investigative Site, Vinnytsia, Ukraine
Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 800
- Registration Number
- NCT01523236
Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 347
- Registration Number
- NCT01470053
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 327
- Registration Number
- NCT01401465
- Locations
- 🇺🇸
The Clinical Research Center, L.L.C., St. Louis, Missouri, United States
🇺🇸Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States
🇺🇸Pharmacuetical Research & Consulting, Inc., Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.